Hot Biotech Celgene Clears Buy Point On Receptos

By | July 15, 2015

Scalper1 News

Celgene (CELG) stock is flying in the stock market today after the big biotech announced late Tuesday that it’s acquiring peer Receptos (RCPT) for $232 a share in cash to enhance its inflammation and immunology portfolio. Along with the $7.2 billion deal, Celgene announced view-topping preliminary Q2 earnings. Shares gapped up 8.2% to 132.88 in huge volume Wednesday, hitting an all-time intraday high of 135.98. The stock also broke out of a cup Scalper1 News

Scalper1 News